Digene to develop DNA test for herpes:
This article was originally published in Clinica
Executive Summary
Digene has received a grant from the US National Institutes of Health to develop a DNA test for the herpes simplex virus (HSV) based on the company's Hybrid Capture II technology. The company plans to use the $750,000 award to develop a simple, sensitive and cost-effective test to improve detection, screening and monitoring of patients with HSV Types 1 and 2 infection. The Beltsville, Maryland-based company estimated that three to five million HSV tests are performed annually in the US, while six to 10 million are carried out worldwide.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.